[{"id":"db692246-7cbb-4fcb-bd5c-6cfbc37eac15","acronym":"","url":"https://clinicaltrials.gov/study/NCT06080776","created_at":"2023-10-12T21:14:03.306Z","updated_at":"2024-07-02T16:35:33.741Z","phase":"Phase 3","brief_title":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","source_id_and_acronym":"NCT06080776","lead_sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sanrisso (rilertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2023-10-12"}]